| 1 |
NCT00002595 |
Completed |
Toremifene in Treating Patients With Desmoid Tumors |
|
- Drug: toremifene
- Procedure: conventional surgery
|
Interventional |
Phase 2 |
- Lutheran General Hospital
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
72 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00002595 |
LGH-1011
CDR0000063797
NCI-V91-0211 |
|
July 1991 |
May 2003 |
September 2010 |
April 22, 2004 |
July 10, 2013 |
|
- Lutheran General Hospital
Park Ridge, Illinois, United States
|
| 2 |
NCT00003019 |
Completed |
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors |
|
- Drug: methotrexate
- Drug: vinblastine sulfate
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Cancer Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
28 |
All |
up to 21 Years (Child, Adult) |
NCT00003019 |
9650
POG-9650
CCG-P9650
CDR0000065601
COG-P9650 |
|
August 1997 |
July 2003 |
September 2006 |
April 30, 2004 |
July 25, 2014 |
|
- Long Beach Memorial Medical Center
Long Beach, California, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 36 more...)
|
| 3 |
NCT01876082 |
Recruiting |
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors |
- Progressive Desmoids Tumors
|
- Drug: PAZOPANIB treatment
- Drug: Active Comparator: Vinblastine and Methotrexate
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy evaluation in terms of non progression rate at 6 months of treatment with Pazopanib
- Efficacy evaluation in terms of non progression rate at 6 months of treatment methotrexate-vinblastine
- In each arm, efficacy evaluation in terms of best response • Progression-free survival • Overall survival Tolerance evaluation Pain assessment Quality of life evaluation Pharmacogenomic Analysis Pharmacokinetic analysis in Pazopanib arm
- (and 3 more...)
|
94 |
All |
18 Years and older (Adult, Senior) |
NCT01876082 |
IB2011-03 |
DESMOPAZ |
July 2012 |
July 2019 |
July 2020 |
June 12, 2013 |
October 5, 2017 |
|
- Institut Bergonié
Bordeaux, Aquitaine, France
|
| 4 |
NCT02476305 |
Completed |
Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Treatment |
|
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-progression of non-abdominopelvic desmoid tumor
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02476305 |
6018 |
CRYODESMO01 |
May 2015 |
November 2017 |
November 2017 |
June 19, 2015 |
November 17, 2017 |
|
- Service d'Imagerie Interventionnelle
Strasbourg, Alsace, France
|
| 5 |
NCT01981551 |
Active, not recruiting |
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis |
- Desmoid Tumors
- Aggressive Fibromatosis
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the response rate (CR+PR) of PF-03084014 in patients with desmoid tumors/aggressive fibromatosis
- Assess symptom measures at baseline and on study; perform genotyping for germline and somatic mutations in APC and CTNNB1 genes; correlate clinical response to therapy with genotyping data; and assess modulation of the Notch pathway by evaluatin...
|
17 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01981551 |
140007
14-C-0007 |
|
October 31, 2013 |
October 12, 2019 |
October 12, 2019 |
November 11, 2013 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 6 |
NCT01265030 |
Recruiting |
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis |
|
|
Interventional |
Phase 1
Phase 2 |
- Maine Medical Center
- Desmoid Tumor Research Foundation
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine if mTor pathway activation decreases in patients with surgically-resectable desmoid tumor removed following pre-operative treatment with sirolimus
- Assess whether sirolimus improves pain
- Explore whether pre-operative sirolimus decreases tumor recurrence following resection of high-risk tumor
- Assess safety and tolerability of pre-operative sirolimus in patients with desmoid
|
15 |
All |
up to 29 Years (Child, Adult) |
NCT01265030 |
10-491-B
44574 |
|
February 2014 |
March 2019 |
March 2019 |
December 22, 2010 |
April 7, 2017 |
|
- UCLA Medical Center
Los Angeles, California, United States - Maine Medical Center
Portland, Maine, United States - Children's Mercy Hospital
Kansas City, Missouri, United States - (and 2 more...)
|
| 7 |
NCT00068419 |
Active, not recruiting
Has Results |
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor |
|
- Drug: tamoxifen citrate
- Drug: sulindac
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free Survival
- Toxicity as Assessed by the National Cancer Institute Common Toxicity Terminology for Adverse Events v3.0
- Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)
- Changes in Magnetic Resonance Imaging (MRI) Signal Features
|
70 |
All |
up to 18 Years (Child, Adult) |
NCT00068419 |
ARST0321
NCI-2009-00424
CDR0000322260
COG-ARST0321
U10CA098543 |
|
February 2004 |
August 2010 |
|
September 11, 2003 |
April 21, 2017 |
December 4, 2013 |
- Children's Oncology Group
Monrovia, California, United States
|
| 8 |
NCT00030680 |
Completed |
Radiation Therapy in Treating Patients With Aggressive Fibromatoses |
|
- Radiation: radiation therapy
|
Interventional |
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Primary Purpose: Treatment
|
- Local control as assessed by MRI at 3 years
- Toxicity as assessed by CTC 2.0
- Response as assessed by MRI
|
44 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00030680 |
EORTC-62991-22998
EORTC-62991
EORTC-22998 |
|
November 2001 |
March 2012 |
March 2012 |
January 27, 2003 |
August 27, 2013 |
|
- Cliniques Universitaires Saint-Luc
Brussels, Belgium - Universitair Ziekenhuis Antwerpen
Edegem, Belgium - Institut Bergonie
Bordeaux, France - (and 18 more...)
|
| 9 |
NCT01137916 |
Completed |
Study to Evaluate Imatinib in Desmoid Tumors |
- Aggressive Fibromatosis
- Desmoid Tumor
|
|
Interventional |
Phase 2 |
- Heidelberg University
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-progression rate after 6 months of treatment
- Non-progression rate after 12 and 24 months of treatment
- Response rate
- (and 2 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT01137916 |
CSTI571BDE70 |
|
June 2010 |
December 2016 |
December 2016 |
June 7, 2010 |
May 3, 2017 |
|
- University of Heidelberg, Mannheim University Medical Center
Mannheim, Germany
|
| 10 |
NCT02374931 |
Active, not recruiting |
18F-FES PET/CT in Imaging Patients With Desmoid Tumors |
- Deep Fibromatosis/Desmoid Tumor
- Familial Adenomatous Polyposis
|
- Drug: F-18 16 Alpha-Fluoroestradiol
- Procedure: Positron Emission Tomography
- Procedure: Computed Tomography
- Other: Laboratory Biomarker Analysis
|
Interventional |
Early Phase 1 |
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Standard uptake value (SUV) measured as percent injected dose per cc
- IHC staining intensity in tissue samples
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT02374931 |
VICC SAR 1458
NCI-2015-00081
P30CA068485 |
|
April 2015 |
July 2017 |
December 2018 |
March 2, 2015 |
April 11, 2018 |
|
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 11 |
NCT00978146 |
Withdrawn |
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors |
- Desmoid Tumors
- Fibromatosis
|
|
Interventional |
Phase 2 |
- Children's Hospital of Philadelphia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome of this study is change in tumor size.
|
0 |
All |
up to 21 Years (Child, Adult) |
NCT00978146 |
09-007317 |
|
October 2009 |
January 2015 |
January 2015 |
September 16, 2009 |
April 20, 2017 |
|
|
| 12 |
NCT02867033 |
Recruiting |
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) |
|
- Procedure: biopsy
- Other: biobank constitution
- Procedure: Coloscopy
- (and 3 more...)
|
Interventional |
Not Applicable |
- Centre Oscar Lambret
- Ligue contre le cancer, France
- Institut Curie
- Hôpital de la Timone
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Incident cases of aggressive fibromatosis
- Number of Aggressive Fibromatosis associated with familial adenomatous polyposis
- Percentage of CTNNB1 mutation in non-selected cases of Aggressive Fibromatosis
- (and 3 more...)
|
600 |
All |
Child, Adult, Senior |
NCT02867033 |
ALTITUDES-1508 |
ALTITUDES |
March 2016 |
June 2021 |
December 2021 |
August 15, 2016 |
October 16, 2017 |
|
- Centre Hospitalier Universitaire
Angers, France - Institut de Cancérologie de l'Ouest - Paul Papin
Angers, France - CHU de Besançon
Besancon, France - (and 36 more...)
|
| 13 |
NCT00928525 |
Active, not recruiting |
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma |
- Advanced Desmoid Tumor
- Advanced Chondrosarcoma
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response will be evaluated by different imaging techniques
|
35 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00928525 |
CSTI571 Basket 1
EudraCT Number: 2006-006446-33 |
Basket 1 |
May 2007 |
December 2018 |
December 2018 |
June 26, 2009 |
April 19, 2018 |
|
- Centro di Riferimento Oncologico - Unit of Medical Oncology
Aviano, Pordenone, Italy - I.R.C.C. - Unit of Medical Oncology
Candiolo, Torino, Italy - Istituti Ortopedici Rizzoli - Unit of chemotherapy of Muscoloskeletal Tumors
Bologna, Italy - (and 4 more...)
|
| 14 |
NCT00287846 |
Completed |
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-progression rate
- Toxic effects
- Tolerance
- (and 5 more...)
|
40 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00287846 |
CDR0000441039
FRE-FNCLCC-SARCOME-05/0401
EU-20515 |
|
September 2004 |
February 2006 |
June 2010 |
February 7, 2006 |
August 30, 2016 |
|
- Centre Paul Papin
Angers, France - Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France - Institut Bergonie
Bordeaux, France - (and 20 more...)
|
| 15 |
NCT03459469 |
Not yet recruiting |
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 |
|
|
Interventional |
Phase 1 |
- Beta Cat Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability
- 1. To determine the durability of response (DOR) to BC2059 after the achievement of best response
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03459469 |
BCI-001-DT17 |
|
March 15, 2018 |
September 1, 2019 |
November 1, 2019 |
March 9, 2018 |
March 12, 2018 |
|
|
| 16 |
NCT02353429 |
Unknown † |
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets |
- Desmoid Type-fibromatosis
|
|
Interventional |
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Associazione Italiana per la Ricerca sul Cancro
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT02353429 |
INT 112/11 |
|
November 2012 |
June 2015 |
December 2015 |
February 2, 2015 |
February 2, 2015 |
|
- Fondazione IRCCS Istituto Tumori Milano
Milan, Italy
|
| 17 |
NCT02547831 |
Unknown † |
Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients |
- Desmoid-type Fibromatosis
|
- Other: Observational approach
|
Observational |
|
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Ministero della Salute, Italy
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Progression free survival
|
100 |
All |
Child, Adult, Senior |
NCT02547831 |
INT 13/12 |
|
July 2013 |
December 2015 |
August 2016 |
September 11, 2015 |
September 11, 2015 |
|
- Fondazione del Piemonte per l' Oncologia - IRCCS
Candiolo, Torino, Italy - Fondazione IRCCS Istituto Tumori Milano
Milan, Italy
|
| 18 |
NCT02066181 |
Active, not recruiting |
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis |
- Desmoid-Type Fibromatosis
|
- Other: Laboratory Biomarker Analysis
- Other: Placebo
- Other: Quality-of-Life Assessment
- Drug: Sorafenib Tosylate
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival
- Incidence of adverse events, using the Patient Reported Outcomes-Common Terminology Criteria in Adverse Events version 4.0
- Time to surgical intervention during treatment
- (and 3 more...)
|
83 |
All |
18 Years and older (Adult, Senior) |
NCT02066181 |
NCI-2014-00264
PA091105_A04PAMDREVW01
1R01FD005105-01A1
A091105
U10CA180821
U10CA031946 |
|
March 21, 2014 |
January 1, 2019 |
|
February 19, 2014 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - PCR Oncology
Arroyo Grande, California, United States - (and 148 more...)
|
| 19 |
NCT01898416 |
Recruiting |
Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors |
- The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an
- Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After
- Surgical Resection
|
- Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
|
Interventional |
Phase 2 |
- michal roll
- Tel-Aviv Sourasky Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint is a binary variable where each patient is classified as a recurrence or a not recurrence case and will be determined by calculating the proportion of recurrence versus non recurrence rates
- To assess the safety of study drug administration in the study population. To assess the 5 years local recurrence rate.
|
140 |
All |
18 Years and older (Adult, Senior) |
NCT01898416 |
TASMC-11-JB-558-CTIL |
|
June 2013 |
December 2023 |
December 2026 |
July 12, 2013 |
October 31, 2013 |
|
- Tel Aviv sourasky medical center
Tel AVIV, Israel - The Aviv Sourasky Medical Center
Tel Aviv, Israel
|
| 20 |
NCT01286662 |
Completed |
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome |
- Gardner Syndrome
- Colorectal Carcinoma
- Desmoid Tumor
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- mortality
- incidence of colorectal carcinoma
- Incidence of desmoid tumors
|
105 |
All |
Child, Adult, Senior |
NCT01286662 |
TriemliH |
|
January 1978 |
December 2010 |
December 2010 |
January 31, 2011 |
January 31, 2011 |
|
|
| 21 |
NCT03275818 |
Recruiting |
Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma |
- Tumor, Desmoplastic Small Round Cell, Adult
- Tumor, Desmoplastic Small Round Cell, Childhood
- Sarcoma, Ewing
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- Grupo Espanol de Investigacion en Sarcomas
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) - cohort 1
- Clinical benefit rate (CBR) - cohort 1
- Objective response rate (ORR) - cohort 2
- (and 5 more...)
|
61 |
All |
6 Months to 80 Years (Child, Adult, Senior) |
NCT03275818 |
GEIS-39
2016-002464-14 |
ABRADES |
May 9, 2017 |
September 30, 2020 |
September 30, 2020 |
September 8, 2017 |
September 8, 2017 |
|
- H. de la Santa Creu i Sant Pau
Barcelona, Spain - H. Sant Joan de Déu
Barcelona, Spain - H.U. 12 de Octubre
Madrid, Spain - (and 4 more...)
|
| 22 |
NCT02955446 |
No longer available |
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies |
|
|
Expanded Access |
|
- University of Colorado, Denver
- Pfizer
|
Other / Industry |
|
|
|
All |
16 Years to 101 Years (Child, Adult, Senior) |
NCT02955446 |
15-2088.cc |
|
|
|
|
November 4, 2016 |
June 20, 2017 |
|
- University of Colorado
Aurora, Colorado, United States
|
| 23 |
NCT02495519 |
Active, not recruiting |
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) |
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- non-progressive rate
- overall survival
|
21 |
All |
10 Years and older (Child, Adult, Senior) |
NCT02495519 |
4-2014-0074 |
|
April 2014 |
March 2018 |
December 2018 |
July 13, 2015 |
January 11, 2018 |
|
- Severance Hospital, Yonsei University Health System
Seoul, Korea, Republic of
|
| 24 |
NCT01273168 |
Active, not recruiting |
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors |
- Hormone Receptor-Positive Breast
- Gynecologic
- Desmoid
- Hormone Receptor-Positive Neoplasms
|
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Establish safety and MTD of Z-endoxifen
- Determine the pharmacokinetics of Zendoxifen (free base and HClforms)
|
40 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01273168 |
110061
11-C-0061 |
|
January 7, 2011 |
October 31, 2018 |
October 31, 2018 |
January 10, 2011 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 25 |
NCT02651246 |
Recruiting |
Optional Sub-study to Intraoperative Imaging With ICG Registry |
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer
- Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
- Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
|
|
Observational |
|
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of tumor recurrence
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT02651246 |
UPCC 31915 |
|
December 2015 |
December 2021 |
|
January 8, 2016 |
July 20, 2016 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 26 |
NCT00474994 |
Completed
Has Results |
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas |
- Adult Malignant Fibrous Histiocytoma of Bone
- Desmoid Tumor
- Endometrial Cancer
- (and 3 more...)
|
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Dana-Farber Cancer Institute
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Objective Response
|
53 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00474994 |
07-054
P30CA008748
MSKCC-07054
PFIZER-MSKCC-07054 |
|
April 2007 |
November 2010 |
November 2010 |
May 17, 2007 |
January 20, 2016 |
January 20, 2016 |
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
| 27 |
NCT02076906 |
Recruiting |
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors |
- Relapsed Pediatric Solid Tumors
- Refractory Pediatric Solid Tumors
- Tumors Located in Bone or Soft Tissue in Close Proximity to Bone
- (and 8 more...)
|
- Device: Magnetic Resonance High Intensity Focused Ultrasound
|
Interventional |
Phase 1 |
- AeRang Kim
- Children's Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity
- Disease response
- Patient reported outcomes and quality of life measurements
- Immune Markers
|
14 |
All |
up to 30 Years (Child, Adult) |
NCT02076906 |
HIFU3917 |
|
April 2014 |
January 2019 |
January 2019 |
March 4, 2014 |
April 3, 2018 |
|
- Children's National Medical Center
Washington, District of Columbia, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 28 |
NCT03422679 |
Recruiting |
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies |
- Advanced or Metastatic Solid Tumours
- Breast Cancer
- Colorectal Cancer
- (and 14 more...)
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part A: Dose limiting toxicity (DLT)
- Part B: antitumour efficacy
- Part A and B: incidence of all adverse events and serious adverse events (safety and tolerability)
- (and 5 more...)
|
165 |
All |
18 Years and older (Adult, Senior) |
NCT03422679 |
CB103-C-101 |
|
December 5, 2017 |
June 30, 2021 |
June 30, 2021 |
February 6, 2018 |
February 6, 2018 |
|
- Academic Medical Center
Amsterdam, Netherlands - Maastricht UMC
Maastricht, Netherlands - UMC Utrecht Cancer Center
Utrecht, Netherlands - (and 4 more...)
|
| 29 |
NCT00919269 |
Active, not recruiting |
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma |
- Adult Rhabdomyosarcoma
- Childhood Desmoplastic Small Round Cell Tumor
- Chordoma
- (and 12 more...)
|
- Other: biologic sample preservation procedure
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection of human tumor tissue and other biological specimens (blood, serum, and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma
- Collection of clinical data on patients who are not being treated on a COG therapeutic study
|
1500 |
All |
up to 50 Years (Child, Adult) |
NCT00919269 |
D9902
NCI-2009-00502
IRS-D9902
CCG-B904
COG-D9902
CDR0000078602
POG-9153
U10CA024507 |
|
March 1999 |
January 2100 |
January 2100 |
June 12, 2009 |
December 13, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 217 more...)
|
| 30 |
NCT01567046 |
Completed |
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas |
- Childhood Alveolar Soft-part Sarcoma
- Childhood Angiosarcoma
- Childhood Desmoplastic Small Round Cell Tumor
- (and 12 more...)
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Frequency of individual mutated genes in patients with NRSTS
- Genetic changes that are most common and likely to have the greatest therapeutic impact
|
70 |
All |
up to 30 Years (Child, Adult) |
NCT01567046 |
ARST12B5
NCI-2012-00714 |
|
May 2016 |
May 2016 |
May 2016 |
March 30, 2012 |
May 17, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
| 31 |
NCT02557854 |
Recruiting |
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors |
- Rhabdomyosarcoma
- Neuroblastoma
- Sarcoma
- (and 3 more...)
|
- Drug: Doxorubicin HCl liposomal injection
- Device: Philips Sonalleve MR-HIFU Hyperthermia
|
Interventional |
Phase 1 |
- Theodore Laetsch
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of dose limiting toxicities (DLTs) during cycle 1 of therapy with MR-HIFU hyperthermia directed liposomal doxorubicin
- Terminal half-life (T1/2) of Doxil when delivered with MR-HIFU hyperthermia
- Volume of distribution (L/m2) of Doxil when delivered with MR-HIFU hyperthermia
- (and 5 more...)
|
14 |
All |
1 Year to 40 Years (Child, Adult) |
NCT02557854 |
UTSW-HIFU-001 |
|
December 2016 |
December 2019 |
December 2020 |
September 23, 2015 |
April 10, 2018 |
|
- UT Southwestern Medical Center/Children's Medical Center
Dallas, Texas, United States
|
| 32 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02834013 |
NCI-2016-01041
S1609
U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
April 26, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 816 more...)
|
| 33 |
NCT01046487 |
Completed |
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate |
|
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Procedure: Blood sampling
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- For safety: NCI-CTCAE scale version 3.0
- For anti tumoral efficiency : RECIST criteria
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT01046487 |
PALANGI-3 0804 |
PALANGI3 |
January 2009 |
April 2011 |
February 2012 |
January 12, 2010 |
June 7, 2012 |
|
- Institut Bergonié
Bordeaux, France - Centre Oscar Lambret
Lille, France - Centre Léon Bérard
Lyon, France
|
| 34 |
NCT00538850 |
Completed
Has Results |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
|
- Drug: Fentanyl sublingual spray
- Drug: Placebo
|
Interventional |
Phase 3 |
- INSYS Therapeutics Inc
- National Cancer Institute (NCI)
|
Industry / NIH |
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)
- Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing
- Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing
- Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT00538850 |
INS-05-001
CDR0000581128 |
|
October 2007 |
February 2010 |
October 2010 |
October 3, 2007 |
March 5, 2014 |
March 5, 2014 |
- InSys Therapeutics, Incorporated
Chandler, Arizona, United States
|
| 35 |
NCT00020579 |
Completed |
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma |
|
|
Interventional |
Phase 1 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicities and maximum tolerated dose
- Pharmacology and pharmacokinetics
- Acetylation of histones in peripheral blood
- Tumor response by CT scan every 12 weeks
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00020579 |
010124
01-C-0124
NCI-2792
CDR0000068615 |
|
March 2001 |
April 2008 |
October 2008 |
January 27, 2003 |
March 15, 2012 |
|
- National Naval Medical Center
Bethesda, Maryland, United States - Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - NCI - Center for Cancer Research
Bethesda, Maryland, United States
|
| 36 |
NCT02228889 |
Recruiting |
Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction |
- Hernia, Ventral
- Intestinal Fistula
- Fibromatosis, Abdominal
|
- Procedure: Abdominal wall reconstruction with Strattice
- Other: Assess pain intensity at last office visit preoperatively
- Other: Assess pain interference at last office visit preoperatively
- (and 17 more...)
|
Interventional |
Phase 4 |
- Jeffrey E Janis, MD
- Ohio State University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Overall complication rate at 1 year
- Rate of Surgical Site Occurrences (SSOs) at 1 year
- Hernia recurrence rate at 30 days
- (and 13 more...)
|
70 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02228889 |
2014H0041 |
|
January 2015 |
December 2020 |
December 2020 |
August 29, 2014 |
April 10, 2018 |
|
- The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
|
Create an RSS feed from your search for:
Download the search results for: